CD8A and neoplasm: This is corroborated by the evidence that the loss of CD8+ T-cells by in vivo treatment with anti-CD8 monoclonal antibodies in immunocompetent mice, impaired the tumor clearance and survival benefits provided by VC2 therapy [17].